Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified lineup of products than ...

Eli Lilly (NYSE: LLY) has been on a roll in recent years, thanks to its leadership in the weight management drug market.

Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.

Eli Lilly working Humana to distribute obesity medications through employer-focused programs via CenterWell Pharmacy.

Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...

A compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it ...

Two days earlier, Eli Lilly and Company (NYSE:LLY) announced a partnership with NVIDIA to develop an AI co-innovation lab ...

Despite Super Bowl rings and big plays, "Manning fatigue" may hurt his case. That would be a shame because Eli was a master ...